[go: up one dir, main page]

EA200000603A1 - Конъюгаты, которые можно использовать при лечении рака предстательной железы - Google Patents

Конъюгаты, которые можно использовать при лечении рака предстательной железы

Info

Publication number
EA200000603A1
EA200000603A1 EA200000603A EA200000603A EA200000603A1 EA 200000603 A1 EA200000603 A1 EA 200000603A1 EA 200000603 A EA200000603 A EA 200000603A EA 200000603 A EA200000603 A EA 200000603A EA 200000603 A1 EA200000603 A1 EA 200000603A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
prostate cancer
treating prostate
periwinkle
dtp
Prior art date
Application number
EA200000603A
Other languages
English (en)
Other versions
EA002745B1 (ru
Inventor
Стефен Ф. Брэди
Донг-Мей Фенг
Виктор М. Гарски
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200000603A1 publication Critical patent/EA200000603A1/ru
Publication of EA002745B1 publication Critical patent/EA002745B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

(57) Раскрыты химические конъюгаты, которые включают олигопептиды, имеющие аминокислотные последовательности, которые избирательно протеолитически расщепляются свободным специфическим антигеном предстательной железы (PSA), и известные цитотоксические средства. Конъюгаты изобретения характеризуются прикреплением расщепляемого олигопептида к атому кислорода в четвертом положении на препарате барвинка, который был дезацетилирован. Такие конъюгаты могут использоваться в лечении рака предстательной железы и доброкачественной гипертрофии предстательной железы (ДТП).Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000603A 1997-12-02 1998-11-25 Конъюгаты, которые можно использовать при лечении рака предстательной железы EA002745B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
EA200000603A1 true EA200000603A1 (ru) 2000-12-25
EA002745B1 EA002745B1 (ru) 2002-08-29

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000603A EA002745B1 (ru) 1997-12-02 1998-11-25 Конъюгаты, которые можно использовать при лечении рака предстательной железы

Country Status (26)

Country Link
US (2) US20060148718A1 (ru)
EP (1) EP1036093A1 (ru)
JP (1) JP2001525337A (ru)
KR (1) KR100580137B1 (ru)
CN (1) CN1181092C (ru)
AR (1) AR016427A1 (ru)
AU (1) AU744652B2 (ru)
BG (1) BG65486B1 (ru)
BR (1) BR9815116A (ru)
CA (1) CA2311615A1 (ru)
DZ (1) DZ2665A1 (ru)
EA (1) EA002745B1 (ru)
EE (1) EE200000333A (ru)
HR (1) HRP20000367A2 (ru)
HU (1) HUP0100350A3 (ru)
ID (1) ID24735A (ru)
IL (1) IL136167A0 (ru)
IS (1) IS5502A (ru)
NO (1) NO20002804L (ru)
NZ (1) NZ504615A (ru)
PE (1) PE20000009A1 (ru)
PL (1) PL197006B1 (ru)
SK (1) SK8282000A3 (ru)
TR (1) TR200002260T2 (ru)
TW (1) TW577897B (ru)
WO (1) WO1999028345A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942128D1 (de) * 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
NZ583931A (en) 2007-08-17 2012-06-29 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9371362B2 (en) * 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
EP2916835A4 (en) * 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
CN105229742A (zh) 2013-04-30 2016-01-06 惠普发展公司，有限责任合伙企业 存储器访问速率
SG11201602249RA (en) 2013-10-18 2016-05-30 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA035171B1 (ru) 2013-11-14 2020-05-08 Эндосайт, Инк. Конъюгаты на основе связывающихся с psma лигандов или ингибиторов psma для позитронно-эмиссионной томографии
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
BR112020020961A2 (pt) 2018-04-17 2021-01-19 Endocyte, Inc. Métodos de tratamento de câncer
CN120097929A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2022136586A1 (en) 2020-12-22 2022-06-30 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
GR81790B (ru) * 1983-04-29 1984-12-12 Omnichem Sa
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
TR200002260T2 (tr) 2000-12-21
NO20002804D0 (no) 2000-05-31
HUP0100350A2 (hu) 2001-08-28
PL340768A1 (en) 2001-02-26
US20060148718A1 (en) 2006-07-06
WO1999028345A1 (en) 1999-06-10
EE200000333A (et) 2001-08-15
BR9815116A (pt) 2000-10-10
JP2001525337A (ja) 2001-12-11
HRP20000367A2 (en) 2000-12-31
EP1036093A1 (en) 2000-09-20
DZ2665A1 (fr) 2003-03-22
NO20002804L (no) 2000-07-21
PL197006B1 (pl) 2008-02-29
HUP0100350A3 (en) 2001-09-28
ID24735A (id) 2000-08-03
CN1284086A (zh) 2001-02-14
IL136167A0 (en) 2001-05-20
CN1181092C (zh) 2004-12-22
SK8282000A3 (en) 2000-11-07
EA002745B1 (ru) 2002-08-29
NZ504615A (en) 2003-05-30
KR100580137B1 (ko) 2006-05-16
AR016427A1 (es) 2001-07-04
CA2311615A1 (en) 1999-06-10
BG65486B1 (bg) 2008-09-30
PE20000009A1 (es) 2000-01-27
IS5502A (is) 2000-05-19
TW577897B (en) 2004-03-01
US20070021350A1 (en) 2007-01-25
AU1612399A (en) 1999-06-16
BG104563A (en) 2001-04-30
AU744652B2 (en) 2002-02-28
KR20010032687A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
EA199900428A1 (ru) Конъюгаты, используемые в лечении рака предстательной железы
EA200000603A1 (ru) Конъюгаты, которые можно использовать при лечении рака предстательной железы
EP1009420A4 (en) CONJUGATES WHICH ARE USEFUL IN TREATING PROSTATE CANCER
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
DK0771209T3 (da) Hidtil ukendte peptider
CY1109614T1 (el) Μορια παρομοια με παραγοντα vii ή viia
NO20020348L (no) Peptid acceptor ligeringsmetoder
TR199901604T2 (xx) Tedavide yararl� kinolin ve kinazolin bile�ikleri.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
WO2003018611A3 (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
ATE356357T1 (de) Prostatakrebs-marker
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
TR200100387T2 (tr) Alkoksilli amin nötralize aromatik sülfonik asit sürfaktanlar içeren pestisid formülasyonları
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
YU34400A (sh) Konjugati korisni u lečenju kancera prostate
WO1999044628A8 (en) Conjugates useful in the treatment of prostate cancer
ES2163921T3 (es) Substancia con actividad renina que contiene prorrenina humana y los anticuerpos contra el profragmento de prorrenina.
WO1993020852A3 (en) Macrocyclic chelating agents, chelates and conjugates thereof
ID28174A (id) Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya
TH55852A (th) คอนจูเกทมีประโยชน์ในการรักษามะเร็งต่อมลูกหมาก
ECSP972297A (es) Conjugados utiles en el tratamiento de cancer de prostata

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU